1Manns MP,McHutchison JG,Gordon SC. Peginterferon alfa2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:a randomised trial[J].The Lancet,2001,(9286):958-965.doi:10.1016/S0140-6736(01)06102-5.
2Fried MW,Shiffman ML,Reddy KR. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection[J].New England Journal of Medicine,2002,(13):975-982.doi:10.1056/NEJMoa020047.
5Kolor B. Patient education and treatment strategies implemented at a pharmacist-managed hepatitis c virus clinic[J].Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy,2005,(09):1230-1241.
3Lok AS. Chronic hepatitis B [ J ]. N Engl J Med, 2002,346 (22) : 1682-1683.
4de Jongh FE, Janssen HL, de Man RA, et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver [ J ]. Gastroenterology, 1992,103 (5) : 1630-1635.
5Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update [J]. Clin Gastroenterol Hepatol, 2006,4 (8): 936-962.
7Akazawa D, Moriyarna M, Yokokawa H, et al. Neutralizing antibodies induced by cell culture - derived hepatitis C virus protect against infec- tion in mice[J]. Gastroenterology,2013,145(2) :447 - 455.
8Pantua H, Diao J, Ultsch M,et al. Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadlyneutra- lizing antibodies[J ]. J Mol Biol,2013,425(11 ) : 1899 - 1914.
9Wahid A, Dubuisson J. Virus- neutralizing antibodies to hepatitis C virus[J]. J Viral Hepat,2013,20(6) :369 - 376.
